Insights & Perspectives

Filter by










Therapeutic Area / Research

Year Starting

Year Ending

Search Insights:
Showing 1 to 10 of 340
Filter by: Unfiltered

Blog Post | Sep 29, 2014

Gilotrif improves PFS in platinum-pretreated head and neck cancer, but is that enough?

Oncology Conference Insight: ESMO 2014 --- Head and neck cancer patients tend to receive chemotherapy doublets with or without the only approved targeted agent, the EGFR antibody Erbitux® (cetuximab, Bristol-Myers Squibb/Lilly/Merck Serono) as first-line therapy. Up to 90% of squamous cell carcinoma of the head and neck (SCCHN) patients have a tumor with EGFR aberrations, and according to Kantar Health’s CancerMPact® Treatment Architecture United States, in 2013 38% of chemotherapy-naïve SCCHN patients received Erbitux as part of their first-line therapy for advanced disease.

Read more | Share

Blog Post | Sep 29, 2014

CLEOPATRA: Overall survival data makes Perjeta the unmistakable queen in first-line HER2+ metastatic breast cancer

Oncology Conference Insight: ESMO 2014 --- The introduction of Herceptin® (trastuzumab, Roche/Genentech) over a decade ago turned HER2+ metastatic breast cancer (MBC) from what was once a patient population with poor prognosis to one with a vastly improved outlook and led the way for an influx of targeted therapies for this population. Now, the armamentarium against HER2+ MBC has expanded and includes several HER2-targeted agents: Tykerb® (lapatinib, GSK), Perjeta® (pertuzumab, Roche/Genentech) and Kadcyla® (ado-trastuzumab, Roche/Genentech).

Read more | Share

Datasheet | Sep 15, 2014

Value Substantiation

In the current evolving healthcare environment, precisely demonstrating the value of a compound is crucial. However, value has different definitions depending on the stakeholder. Whether it is clinical value for physicians, quality of life for patients, or direct and indirect costs for payers, value drivers are numerous and can easily overlap.

Read more | Share

Newsletter | Sep 3, 2014

Kantar Health Catalyst, September 2014

Read more | Share

Blog Post | Sep 2, 2014

Using online communities to embrace change in healthcare research

Today’s technology makes it so simple for the least tech-savvy to set up and execute an online research forum or community, yet healthcare companies are slow to embrace these opportunities to engage patients for research purposes. This blog reviews the applications and benefits of market research online communities and forums for pharma market research.

Read more | Share

Blog Post | Aug 22, 2014

Will reclassification of hydrocodone products place added burden on pain patients and the healthcare system?

Pain is a huge market. I’ve had pain, and you have too. You might be experiencing pain right now. It’s estimated that more than a billion people worldwide are dealing with pain in one form or another. It can range from acute (like a headache) to chronic (like arthritis). It can be difficult to treat because people experience pain so differently. What one person considers mild pain, another might rate as severe.

Read more | Share

Newsletter | Aug 18, 2014

Kantar Health Catalyst, August 2014

Read more | Share

Blog Post | Aug 18, 2014

Social Listening: Gathering insights through the authentic “voice of the patient”

The social media environment currently provides thousands of online outlets for patients across all disease areas to discuss healthcare issues, and patients are talking in ever-growing numbers. This has resulted in the availability of large volumes of online patient-to-patient discussions around issues that are directly relevant to many of the business issues facing the pharmaceutical industry. It is imperative to tap into the content of these discussions to provide true, actionable recommendations around these business issues.

Read more | Share

Blog Post | Jul 31, 2014

Brand marketing is dead. Long live brand marketing!

In pharma, you need a cohesive approach to brand marketing that must embrace three key elements: Rigorous, evidence-based “scientific” planning to properly understand your brand position and opportunities; coordination across the payer-, prescriber- and patient-focused teams; and forward-looking strategy and executable implementation that is constantly looking for improvements.

Read more | Share

White Paper | Jul 25, 2014

Key Findings from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

This issue of Oncology Conference Insight highlights significant information presented at ASCO 2014, which took place May 30-June 3 in Chicago, Illinois. Our goal is to provide our clients with the latest information presented at oncology meetings.

Read more | Share
Page  < 123456789 >